VIB launches new Agtech spin-off Rainbow Crops to develop climate-resilient crop varieties

Ghent, Belgium, 29 April 2025 – VIB proudly announces the launch of its latest spin-off, Rainbow Crops, a next-generation Agtech company focused on engineering complex, high-value agronomic traits that have long been difficult to address. Through an AI-powered technology platform that combines multiplex genome editing and precision breeding, Rainbow Crops develops crop varieties that are both climate resilient and optimized for yield and other key traits. The company is backed by a strong syndicate of early-stage investors, including Agri Investment Fund (AIF), PINC (the venture capital arm of Paulig Group), Qbic and VIB.

Rainbow Crops has developed an integrated platform, Trait Foundry™, that combines continuously trained AI models with multiplex genome editing, precision breeding, and automated phenotyping. This technology enables the simultaneous enhancement of multiple traits by generating and testing rationally designed genetic diversity across a wide range of crop species. The platform’s scalability and applicability have already been demonstrated through initial proof-of-concept work.

The company is targeting key agronomic traits such as drought tolerance, heat resilience and input efficiency – critical traits in the face of climate change that have long been difficult to improve through traditional plant breeding. The platform’s AI engine is continuously refined using in-house generated phenotypic and genotypic data, improving trait prediction and platform performance over time.

The company is led by serial biotech entrepreneur Giacomo Bastianelli who joins as Co-founder and CEO of Rainbow Crops. “When I first met with the VIB scientists behind the technology, I was impressed by the results, which revealed a transformative approach to engineering complex traits,commented Giacomo Bastianelli.We’re forging partnerships with seed and breeding companies to co-develop next-generation crop genetics that tackle the challenges of tomorrow’s agri-food systems.”
Giacomo Bastianelli, CEO

Rainbow Crops is built on a solid scientific foundation. Prof. Hilde Nelissen, a leading researcher at the VIB-UGent Center for Plant Systems Biology, is one of the scientific founders and will continue to support the company as a scientific advisor. The underlying technology is based on an European Research Council (ERC) grant, awarded to Prof. Dirk Inzé under the EU’s Horizon 2020 Research and Innovation Program.

The company launches operations with the support of a strong syndicate of European investors. The group - comprising the Agri Investment Fund (AIF), PINC (the venture capital arm of Paulig Group), Qbic, and VIB - brings deep expertise across agriculture, foodtech, and the commercialization of early-stage innovation, reinforcing Rainbow Crops' strategic positioning from day one.

Headquartered at the new Bio-Incubator on the Eilandje site in Ghent, Rainbow Crops benefits from VIB’s extensive infrastructure - including state-of-the-art greenhouses and the VIB Agro-Incubator – designed to accelerate early-stage Agtech innovation and support R&D scale-up.

The launch of Rainbow Crops highlights VIB’s ongoing commitment to fostering a vibrant Agtech innovation ecosystem,added Jérôme Van Biervliet, Managing Director at VIB. “By combining scientific excellence with a forward-looking and technology-driven approach, Rainbow Crops is uniquely positioned to drive meaningful impact in global agriculture.

 

Notes to Editors

About VIB

VIB is a leading life sciences research institute based in Belgium, operating in close partnership with the Flemish universities and renowned for its work in medical sciences, plant biology, microbiology, artificial intelligence and biotechnology. VIB's mission is to push the boundaries of scientific discovery, transform it into disruptive biotech innovations and support the growth of the life sciences ecosystem in Flanders (Belgium). ​

VIB drives the translation of research discoveries into innovative products and technologies for patients and society. It does so by launching new spin-offs, licensing intellectual property to companies, engaging in dynamic partnerships and fostering talent development. VIB has created 40 spin-offs in the healthcare and agrifood sectors, attracting almost €2 billion in equity investment and has partnered intensely with private industry, generating over €350 million in income. VIB’s research has led to dozens of innovative products brought to market for medical, agriculture, and food applications, with many more in development. Seven of its spin-off companies have reached the clinical stage.

Learn more at www.vib.be.

 

For more information, please contact:

Rainbow Crops

Giacomo Bastianelli, CEO

E: giacomo.bastianelli@vib.be

M: +39 388 49 10 858

 

VIB Investor Relations

Lies Vanneste

E: IR@vib.be

M: +32 498 05 35 79

 

 

 

Share

Latest stories

Website preview
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-based Biotherapeutic Product Pipeline
Ghent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
press.vib.be
Website preview
Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Groundbreaking Macrophage-Targeted Cancer Therapy
Antwerp, Belgium - 27 August, 2025 - Spica Therapeutics, a pioneering biotech company focused on harnessing macrophage biology to develop transformative therapies across multiple disease areas, announced today that it has been awarded a €1.0 million grant from Flanders Innovation & Entrepreneurship (VLAIO).
press.vib.be
Website preview
Scientists map dendritic cell reactions to vaccines 
Ghent, 26 August 2025 – Belgian scientists have uncovered new details about how the immune system responds to vaccines. Dendritic cells, which are key immune messengers that help kick-start the body’s defenses, show specific responses to lipid nanoparticles. These findings, published in Cell Reports, could lead to safer and more effective vaccines.  
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be